Many of you have asked what makes DEZAWA MUSECells® different — and why we chose this path.

In sharing this, I’m drawing from information provided by the team at Neorgana, including materials from their website and conversations with the physicians there, who have helped us better understand the science behind this approach.

MUSE cells (Multilineage-differentiating Stress Enduring cells) were first identified by Mari Dezawa. What makes them remarkable is that they aren’t engineered or artificially manipulated — they are a naturally occurring, rare subpopulation of regenerative cells with unique biological properties.

Unlike many conventional stem cells, MUSE cells are stress-enduring. They can home to areas of injury, survive in inflamed environments, integrate into damaged tissue, and differentiate into the specific cell types needed for repair — including neural cells. That combination is what caught our attention.

Most stem cell therapies today use Mesenchymal stem cells (MSCs). MSCs absolutely have value — particularly in reducing inflammation and supporting the body’s natural repair processes. But research shows that a large percentage — often cited around 90–95% — do not survive long after administration. Their primary impact is indirect signaling, and they typically do not integrate into damaged tissue.

For us, that distinction matters.

We weren’t simply looking for temporary signaling support. We were looking for a strategy that might contribute more directly to biological repair.

Another reason we felt confident moving forward is the level of selectivity involved. The cells are sourced from umbilical cord tissue and undergo an exceptionally rigorous screening process. A hospital partner may review approximately 100 donated cords — yet only about 3 meet the strict criteria required for clinical use. That level of screening reflects a deep commitment to quality and viability.

And importantly, this protocol isn’t just about cells.

It combines MUSECells® with metabolic conditioning, neurotrophic support, and structured post-treatment consolidation. The goal is to create an internal environment that supports repair and functional progress over time— not just a single intervention, but a coordinated biological strategy.

Your support has given us the opportunity to pursue something that feels hopeful — something that isn’t just about managing day-to-day challenges, but about truly working toward deeper healing.

We don’t take that lightly. And we are deeply grateful to have you on this journey with us.